EXACT Therapeutics
Per Walday has 30+ years’ experience developing pharmaceuticals from early preclinical to commercialisation. Previously, he was the CEO of PCI Biotech, managing development of drug-device combinations through FDA and EMA regulatory paths to late-stage development. His earlier positions include Global Head of Project Management GE Healthcare, with responsibility for all development programmes of new pharmaceuticals.
EXACT Therapeutics
1 followers
EXACT Therapeutics is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT®sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.